IMBiologics Corp. (KOSDAQ:493280)

South Korea · Delayed Price · Currency is KRW

20,250

-1,150 (-5.37%)

At close: Jun 26, 2026

-80.53% (1Y)

Market Cap	299.78B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	14.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,926
Open	21,150
Previous Close	21,400
Day's Range	19,800 - 22,200
52-Week Range	19,800 - 104,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About IMBiologics

IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2020

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 493280

Full Company Profile